Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Adalimumab
M923 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| M923 | BIOLOGICAL | Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) |
| Humira | BIOLOGICAL | Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) |
| Autoinjector | DEVICE | Subcutaneous administration |
M923 is an investigational monoclonal antibody developed by Johnson & Johnson for chronic plaque psoriasis and rheumatoid arthritis. It is in Phase 3 clinical development. M923 has been studied in completed Phase 3 trials, including a study in chronic plaque-type psoriasis and a usability study in moderate to severe rheumatoid arthritis.
M923 is being developed for the treatment of chronic plaque psoriasis, a skin condition characterized by raised, scaly plaques. A completed Phase 3 study evaluated M923 in subjects with chronic plaque-type psoriasis. M923 is also being developed for rheumatoid arthritis. It remains investigational and is not approved for these indications.
M923 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. Johnson & Johnson is the sponsor of the Phase 3 clinical program evaluating M923 in chronic plaque psoriasis and rheumatoid arthritis.
M923 is in Phase 3 clinical development. Two completed Phase 3 trials have evaluated M923: a study in chronic plaque-type psoriasis and a usability study in moderate to severe rheumatoid arthritis. M923 is investigational and has not been approved for any indication.
M923 has been evaluated in completed Phase 3 trials. NCT02581345 was a Phase 3 study of M923 and Humira in subjects with chronic plaque-type psoriasis, enrolling 572 participants. NCT02722044 was a Phase 3 usability study of M923 in subjects with moderate to severe rheumatoid arthritis, enrolling 33 participants.